New Hope for Advanced Prostate Cancer
/A study has proclaimed that the new drug, abiraterone, lowers patients' risk of death by nearly 40 percent when added to standard androgen deprivation therapy (ADT). It also appears to more than double the average time it takes for prostate cancer to progress.
Read More